06 Dec 2018

Novartis has received the European Union’s approval for their Luxturna gene therapy to ensure the return of vision to the people who are suffering from rare retinal disease. Luxturna is an effective one-time treatment for both children and adults who have vision impairments due to mutations from an early age in RPE65 gene. This type of blindness can affect 1 in 200,000 people due to DNA mutations, as per Novartis. This authorization is valid in all the 28 states of EU including Iceland, Liechtenstein and Norway. Luxturna was developed and is now commercialized by Spark Therapeutics in the US.

The Ultimate Pharma Guide

©2020 Copyright. All rights reserved. Powered by . Designed by Hats-Off

Log in with your credentials

Forgot your details?